UNICYCIVE THERAPEUTICS, INC. Fair Value Adjustment of Warrants
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Fair Value Adjustment of Warrants of -$7.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$7.98M.
- UNICYCIVE THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was $4.78M.
- UNICYCIVE THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $7.77M, a 38.14% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$1.07M.
- UNICYCIVE THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2025 was -$2.02M, a 134.83% decline from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2024 was $5.80M, a 43.69% decline from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2023 was $10.30M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.98M 10-Q · filed 2026-08-12 | -$3.20M 10-Q · filed 2026-08-12 | $4.57M derived: sum of 3 quarters · filed 2026-08-12 | $3.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $4.78M 10-Q · filed 2026-05-12 | $12.55M derived: sum of 2 quarters · filed 2026-05-12 | $11.48M derived: sum of 3 quarters · filed 2026-05-12 | $11.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.70M derived: sum of 2 quarters · filed 2026-03-30 | $6.33M derived: sum of 3 quarters · filed 2026-08-12 | -$2.02M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$1.07M 10-Q · filed 2025-11-12 | -$1.44M derived: sum of 2 quarters · filed 2026-08-12 | -$9.79M 10-Q · filed 2025-11-12 | $2.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$374.00K 10-Q · filed 2026-08-12 | -$8.72M 10-Q · filed 2026-08-12 | $3.84M derived: sum of 3 quarters · filed 2026-08-12 | $2.08M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$8.35M 10-Q · filed 2026-05-12 | $4.21M derived: sum of 2 quarters · filed 2026-05-12 | $2.46M derived: sum of 3 quarters · filed 2026-05-12 | -$14.35M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $12.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $10.80M derived: sum of 2 quarters · filed 2026-03-30 | -$6.01M derived: sum of 3 quarters · filed 2026-03-30 | $5.80M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$1.75M 10-Q · filed 2025-11-12 | -$18.56M derived: sum of 2 quarters · filed 2025-11-12 | -$6.76M 10-Q · filed 2025-11-12 | -$5.15M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$16.81M 10-Q · filed 2025-08-14 | -$5.00M 10-Q · filed 2025-08-14 | -$3.40M derived: sum of 3 quarters · filed 2025-08-14 | -$4.79M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $11.81M 10-Q · filed 2025-05-14 | $13.41M derived: sum of 2 quarters · filed 2025-05-14 | $12.02M derived: sum of 3 quarters · filed 2025-05-14 | $11.74M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $210.00K derived: sum of 2 quarters · filed 2025-03-31 | -$72.00K derived: sum of 3 quarters · filed 2025-03-31 | $10.30M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$1.40M 10-Q · filed 2024-11-13 | -$1.68M derived: sum of 2 quarters · filed 2024-11-13 | $8.70M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$282.00K 10-Q · filed 2024-08-14 | $10.09M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $10.38M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |